Immunotherapy continues to take over in a world where cancer rules.
Cancer patients see hope for life, but unfortunately it is hard for patients to know if they are actually the ones who are immunotherapy zapped.
Current clinical statistics show that PD-1 inhibitors only work in 20-50% of patients with advanced solid tumors . Who exactly are the beneficiary patients? Current means of locating these patients are limited.
Therefore, finding a reliable biomarker to guide immunotherapy is imminent!
Recently, Dr. Eric Deutsch's team from France has given us new hope with the power of artificial intelligence. They trained the AI with CT images of cancer patients to get an AI platform that can accurately predict the effect of PD-1 inhibitor treatment from the patient's CT images.